Clinical Trial Update: Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for anlotinib in patients with platinum resistant or refractory ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Ovarian Cancer | Phase 2 | Status: UNKNOWN